Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Trillium Therapeutics Inc. T.TRIL

Trillium Therapeutics Inc is a clinical-stage immuno-oncology company that is engaged in developing therapies for the treatment of cancer. It has two clinical programs, TTI-621 and TTI-622, that target CD47. The company operates in the United States and Canada.


TSX:TRIL - Post by User

Bullboard Posts
Post by noodleyon Sep 12, 2010 8:54pm
712 Views
Post# 17439265

partner

partneri think the guesstimate on phase 3 trial is 40 million...give or take a handful.  chump change for big pharma.  and sct has gotta have a partner here.  same as it was prior to the 25 may waterfall. 

sure was nice to see an nr without the word "but"in it.  maybe the pipeline people are kicking some "but". 

alan's got the ammo he needs for a decent shot on phase 3 meeting with fda.  imo...he'll get it.  The '"objective"...according to the june nr...was a meeting with fda in october.  same as it was prior to 25 may waterfall.  If october is correct....we'll likely get thumbs up (or down) in late december or early January, wouldn't ya think?  Between that...and updates on 2a tbi trial....sct has milestones that can be measured.  that's what will drive the sp.  

and if sct passes the tests and gets to phase 3....you'd have to think they'd be a nice target for big pharma.  2011 oughta be real interesting....

 
Bullboard Posts